Corgenix Medical completes feasibility stage for new test format

Corgenix Medical has completed the feasibility stage for a new, high-speed automated test format for its AspirinWorks Test.

Developed in collaboration with Randox Laboratories, the new format will make it faster and easier to perform the AspirinWorks Test at clinical laboratories and hospitals around the world.

AspirinWorks is a simple urine test to measure levels of 11-dehydro thromboxane B2 (11dhTxB2) to determine aspirin effect in apparently healthy individuals.

The goal of aspirin therapy is to reduce levels of thromboxane in the blood, decreasing platelet stickiness, and therefore reducing the chance of forming a blood clot.

Corgenix president and CEO Douglass Simpson said they have taken another critical step forward in expanding the potential market for the AspirinWorks Test.

"The next step in this process will be the launch of the new fully automated immunoturbidimetric (IT) format, making it easier and faster to process large volumes of this important cardiovascular test," Simpson said.

The assay will be manufactured at Randox Laboratories in the UK, and the two companies will share global distribution rights.